argenx SE (NASDAQ:ARGX - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $546.22, but opened at $571.42. argenx shares last traded at $579.12, with a volume of 128,839 shares trading hands.
Analysts Set New Price Targets
A number of analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft raised argenx from a "sell" rating to a "hold" rating in a report on Wednesday, March 12th. William Blair reiterated an "outperform" rating on shares of argenx in a research note on Friday, February 28th. Wedbush restated an "outperform" rating and set a $715.00 target price on shares of argenx in a research report on Friday, April 11th. Sanford C. Bernstein raised argenx from a "market perform" rating to an "outperform" rating in a report on Monday, March 17th. Finally, Guggenheim lifted their target price on shares of argenx from $775.00 to $1,100.00 and gave the company a "buy" rating in a research report on Monday, March 10th. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, argenx has an average rating of "Moderate Buy" and a consensus target price of $690.33.
Read Our Latest Analysis on argenx
argenx Trading Down 2.7 %
The stock has a market cap of $35.79 billion, a PE ratio of -669.32 and a beta of 0.60. The business has a fifty day simple moving average of $605.51 and a two-hundred day simple moving average of $604.95.
argenx (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. On average, research analysts predict that argenx SE will post 3.13 earnings per share for the current year.
Institutional Investors Weigh In On argenx
A number of large investors have recently added to or reduced their stakes in ARGX. Stephens Inc. AR purchased a new stake in shares of argenx during the 4th quarter valued at about $310,000. Ritholtz Wealth Management increased its holdings in argenx by 85.5% in the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock worth $552,000 after acquiring an additional 414 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in argenx by 1,016.7% during the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after purchasing an additional 61 shares in the last quarter. Park Avenue Securities LLC boosted its position in shares of argenx by 40.0% in the fourth quarter. Park Avenue Securities LLC now owns 1,695 shares of the company's stock worth $1,042,000 after purchasing an additional 484 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of argenx in the third quarter worth $652,000. Institutional investors own 60.32% of the company's stock.
argenx Company Profile
(
Get Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Featured Stories
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
